Cerus logo

CERS - Cerus Share Price

$7.04 0.3  3.7%

Last Trade - 02/12/20

Mid Cap
Market Cap £846.0m
Enterprise Value £778.5m
Revenue £79.9m
Position in Universe 2384th / 6444
Unlock CERS Revenue
Relative Strength (%)
1m +18.2%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
36.4 34.2 39.3 51.3 76.1 93.8 112.3 132.1 +20.8%
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, CerusCorporation revenues increased 20% to $80.7M. Net lossdecreased 16% to $45.5M. Revenues reflect Product revenueincrease of 19% to $63.7M, Government contract revenueincrease of 25% to $16.9M. Lower net loss reflects Interestexpense decrease of 45% to $2.8M (expense), Foreignexchange gain (loss) increase from $311K (expense) to $540K(income), Selling.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


CERS Revenue Unlock CERS Revenue

Net Income

CERS Net Income Unlock CERS Revenue

Normalised EPS

CERS Normalised EPS Unlock CERS Revenue

PE Ratio Range

CERS PE Ratio Range Unlock CERS Revenue

Dividend Yield Range

CERS Dividend Yield Range Unlock CERS Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CERS EPS Forecasts Unlock CERS Revenue
Profile Summary

Cerus Corporation is a biomedical products company. The Company is engaged in developing and commercializing the INTERCEPT Blood System for blood safety. The Company operates through blood safety segment. The Company's INTERCEPT Blood System is based on its technology for controlling biological replication, and is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The Company's INTERCEPT Blood System is designed to target and inactivate blood-borne pathogens, such as viruses, including human immunodeficiency virus (HIV), West Nile, Severe acute respiratory syndrome (SARS), hepatitis B and C; bacteria and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma and red blood cell transfusion products. The Company's INTERCEPT Blood System is for use with blood components, including plasma, platelets, and red blood cells.

Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated July 31, 1996
Public Since January 31, 1997
No. of Shareholders: 135
No. of Employees: 254
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 167,141,975
Free Float (0.0%)
Eligible for
CERS Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for CERS
Upcoming Events for CERS
Frequently Asked Questions for Cerus
What is the Cerus share price?

As of 02/12/20, shares in Cerus are trading at $7.04, giving the company a market capitalisation of £846.0m. This share price information is delayed by 15 minutes.

How has the Cerus share price performed this year?

Shares in Cerus are currently trading at $7.04 and the price has moved by 62.44% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cerus price has moved by 38.74% over the past year.

What are the analyst and broker recommendations for Cerus?

Of the analysts with advisory recommendations for Cerus, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Cerus is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Cerus next release its financial results?

Cerus is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the Cerus dividend yield?

Cerus does not currently pay a dividend.

Does Cerus pay a dividend?

Cerus does not currently pay a dividend.

When does Cerus next pay dividends?

Cerus does not currently pay a dividend.

How do I buy Cerus shares?

To buy shares in Cerus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Cerus?

Shares in Cerus are currently trading at $7.04, giving the company a market capitalisation of £846.0m.

Where are Cerus shares listed? Where are Cerus shares listed?

Here are the trading details for Cerus:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CERS
What kind of share is Cerus?

Based on an overall assessment of its quality, value and momentum, Cerus is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Cerus share price forecast 2020?

Shares in Cerus are currently priced at $7.04. At that level they are trading at 36.97% discount to the analyst consensus target price of 0.00.

Analysts covering Cerus currently have a consensus Earnings Per Share (EPS) forecast of -0.37 for the next financial year.

How can I tell whether the Cerus share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cerus. Over the past six months, the relative strength of its shares against the market has been 2.36%. At the current price of $7.04, shares in Cerus are trading at 14.44% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Cerus PE Ratio?

We were not able to find PE ratio data for Cerus.

Who are the key directors of Cerus?

Cerus's management team is headed by:

Laurence Corash - CSO
Timothy Anderson - IND
Gail Schulze - IND
William Greenman - CEO
Carol Moore - SVP
Kevin Green - CFO
Daniel Swisher - CHM
Chrystal Menard - OTH
Richard Benjamin - OTH
Vivek Jayaraman - COO
Timothy Moore - IND
Eric Bjerkholt - IND
Jami Nachtsheim - IND
Who are the major shareholders of Cerus?

Here are the top five shareholders of Cerus based on the size of their shareholding:

ARK Investment Management LLC Investment Advisor
Percentage owned: 17.95% (30.0m shares)
ARK Innovation ETF Mutual Fund
Percentage owned: 11.53% (19.3m shares)
Baker Bros. Advisors LP Hedge Fund
Percentage owned: 8.2% (13.7m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.02% (11.7m shares)
PRIMECAP Odyssey Aggressive Growth Fund Mutual Fund
Percentage owned: 6.44% (10.8m shares)
Similar to CERS
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.